BioCentury | Sep 23, 2013
Company News

Bone Therapeutics management update

...Therapeutics S.A. , Gosselies, Belgium Business: Musculoskeletal Hired: Wim Goemaere as CFO, formerly CFO of Devgen N.V....
BioCentury | Mar 4, 2013
Company News

Devgen, Syngenta deal

...Syngenta said that as of Feb. 26, 98.32% of agbio company Devgen shares had been tendered...
...results of which will be announced on March 5, it will own 100% of Devgen. Devgen...
...announced plans to acquire Devgen for €16 per share, or about €403 million ($522.8 million). Devgen...
BioCentury | May 21, 2012
Emerging Company Profile

Amakem: Switching off side effects

...technology with a Rho kinase inhibitor for glaucoma. Amakem acquired the technology and therapeutics from Devgen N.V....
...Amakem N.V. , Diepenbeek, Belgium Association for Research in Vision and Ophthalmology , Rockville, Md. Devgen N.V....
BioCentury | Feb 15, 2010
Company News

Amakem, Devgen deal

...Newco Amakem acquired Devgen's preclinical kinase inhibitor program. The lead program is an unnamed Rho-associated coiled-coil...
...inhibitors with localized activity to treat glaucoma, allergic asthma and chronic obstructive pulmonary disease (COPD). Devgen...
...21% stake in the newco (see BioCentury, Nov. 10, 2008). Amakem N.V. , Diepenbeek, Belgium Devgen N.V....
BioCentury | Feb 15, 2010
Company News

Amakem board of directors update

...and financial expert at Life Science Research Partners, as chairman; Thierry Bogaert, managing director at Devgen N.V....
BioCentury | Dec 8, 2008
Company News

Ascent management update

...Jones as president, CEO and a director, formerly head of the pharma business unit of Devgen N.V....
BioCentury | Nov 18, 2008
Financial News

Ascent raises $19 million

...as president and CEO. Jones, who was formerly head of the pharma business unit of Devgen...
BioCentury | Nov 10, 2008
Company News

Devgen agbio/environmental, autoimmune news

...had planned to divest its portfolio of preclinical candidates but could not find a buyer. Devgen's...
...compound is CDE6963, a selective Rho-associated kinase (ROCK) inhibitor to treat inflammatory bowel disease (IBD). Devgen N.V....
BioCentury | Jun 2, 2008
Finance

Next BioTech

...€88.1 Biotech (Pricaf) (Euronext:BIOT) €19.3 Cellectis (Euronext:ALCLS) €66.0 Cerep (Euronext:CER) €57.6 Crucell (Euronext:CRXL; NASDAQ:CRXL) €801.8 Devgen...
BioCentury | Dec 17, 2007
Company News

Devgen management update

Devgen N.V. (Euronext:DEVG), Ghent, Belgium Business: Functional genomics Hired: Wim Goemaere as CFO, formerly CFO at the Flanders Interuniversity Institute of Biotechnology; he replaces Hilde Windels, who will head DEVG's pharma business unit WIR Staff...
Items per page:
1 - 10 of 52
BioCentury | Sep 23, 2013
Company News

Bone Therapeutics management update

...Therapeutics S.A. , Gosselies, Belgium Business: Musculoskeletal Hired: Wim Goemaere as CFO, formerly CFO of Devgen N.V....
BioCentury | Mar 4, 2013
Company News

Devgen, Syngenta deal

...Syngenta said that as of Feb. 26, 98.32% of agbio company Devgen shares had been tendered...
...results of which will be announced on March 5, it will own 100% of Devgen. Devgen...
...announced plans to acquire Devgen for €16 per share, or about €403 million ($522.8 million). Devgen...
BioCentury | May 21, 2012
Emerging Company Profile

Amakem: Switching off side effects

...technology with a Rho kinase inhibitor for glaucoma. Amakem acquired the technology and therapeutics from Devgen N.V....
...Amakem N.V. , Diepenbeek, Belgium Association for Research in Vision and Ophthalmology , Rockville, Md. Devgen N.V....
BioCentury | Feb 15, 2010
Company News

Amakem, Devgen deal

...Newco Amakem acquired Devgen's preclinical kinase inhibitor program. The lead program is an unnamed Rho-associated coiled-coil...
...inhibitors with localized activity to treat glaucoma, allergic asthma and chronic obstructive pulmonary disease (COPD). Devgen...
...21% stake in the newco (see BioCentury, Nov. 10, 2008). Amakem N.V. , Diepenbeek, Belgium Devgen N.V....
BioCentury | Feb 15, 2010
Company News

Amakem board of directors update

...and financial expert at Life Science Research Partners, as chairman; Thierry Bogaert, managing director at Devgen N.V....
BioCentury | Dec 8, 2008
Company News

Ascent management update

...Jones as president, CEO and a director, formerly head of the pharma business unit of Devgen N.V....
BioCentury | Nov 18, 2008
Financial News

Ascent raises $19 million

...as president and CEO. Jones, who was formerly head of the pharma business unit of Devgen...
BioCentury | Nov 10, 2008
Company News

Devgen agbio/environmental, autoimmune news

...had planned to divest its portfolio of preclinical candidates but could not find a buyer. Devgen's...
...compound is CDE6963, a selective Rho-associated kinase (ROCK) inhibitor to treat inflammatory bowel disease (IBD). Devgen N.V....
BioCentury | Jun 2, 2008
Finance

Next BioTech

...€88.1 Biotech (Pricaf) (Euronext:BIOT) €19.3 Cellectis (Euronext:ALCLS) €66.0 Cerep (Euronext:CER) €57.6 Crucell (Euronext:CRXL; NASDAQ:CRXL) €801.8 Devgen...
BioCentury | Dec 17, 2007
Company News

Devgen management update

Devgen N.V. (Euronext:DEVG), Ghent, Belgium Business: Functional genomics Hired: Wim Goemaere as CFO, formerly CFO at the Flanders Interuniversity Institute of Biotechnology; he replaces Hilde Windels, who will head DEVG's pharma business unit WIR Staff...
Items per page:
1 - 10 of 52